TORONTO, Canada I May 21, 2014 I Antibe Therapeutics Inc. (ATE.V) is pleased to announce the submission of a Clinical Trial Application (“CTA”) to Health Canada for its lead drug, ATB-346. The CTA proposes the initiation of a clinical study entitled “A Double-Blind, Placebo-Controlled, Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single/Multiple Ascending Doses of ATB-346 Orally Administered in Healthy Male and Female Subjects.” The submission represents a significant milestone on a well-defined pathway for the development of ATB-346.
Dan Legault, Antibe’s CEO, said “We are delighted to have advanced efficiently to this stage in the development of ATB-346 and look forward to further investigation of its pharmacokinetics and safety in healthy human subjects in our planned Phase I clinical program scheduled to begin this summer.”
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc. develops safer medicines for pain and inflammation. These medicines are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, chemical substances produced in the human body to regulate a range of fundamental cellular processes. The Corporation’s drug design approach involves chemically linking an existing off-patent drug (“base drug”) to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation, pain or vascular dysfunction, this design approach can efficiently produce improved versions of existing drugs.
SOURCE: Antibe Therapeutics
Post Views: 128
TORONTO, Canada I May 21, 2014 I Antibe Therapeutics Inc. (ATE.V) is pleased to announce the submission of a Clinical Trial Application (“CTA”) to Health Canada for its lead drug, ATB-346. The CTA proposes the initiation of a clinical study entitled “A Double-Blind, Placebo-Controlled, Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single/Multiple Ascending Doses of ATB-346 Orally Administered in Healthy Male and Female Subjects.” The submission represents a significant milestone on a well-defined pathway for the development of ATB-346.
Dan Legault, Antibe’s CEO, said “We are delighted to have advanced efficiently to this stage in the development of ATB-346 and look forward to further investigation of its pharmacokinetics and safety in healthy human subjects in our planned Phase I clinical program scheduled to begin this summer.”
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc. develops safer medicines for pain and inflammation. These medicines are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, chemical substances produced in the human body to regulate a range of fundamental cellular processes. The Corporation’s drug design approach involves chemically linking an existing off-patent drug (“base drug”) to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation, pain or vascular dysfunction, this design approach can efficiently produce improved versions of existing drugs.
SOURCE: Antibe Therapeutics
Post Views: 128
